VivoSeq
Oncology

Childhood Leukemia

8

Pipeline Programs

0

Active Trials

7

Companies Involved

Childhood Leukemia is an early-stage landscape with 8 programs across 7 companies. The most active players are Novartis, Daiichi Sankyo, Jazz Pharmaceuticals. 6 therapies are approved.

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

N/A

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSProtein / enzyme114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)